Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Today, we talk lots about clinical trial inconsistencies: How Canada’s trial reporting is not up to snuff, and how companies perpetually want to spin results to make their experimental medicine look more favorable. We also talk about how the ARIA stemming from Alzheimer’s drugs isn’t taken seriously enough, and how state and local governments are suing insulin makers over drug prices.
The need-to-know this morning
• Belgian drugmaker Argenx said its antDesmoid tumor approvalibody medicine failed to achieve the goals of a late-stage study for a platelet-destroying autoimmune disorder — a setback in the company’s efforts to expand the drug’s use.
• A similar antibody for autoimmune diseases being developed by Immunovant, an offshoot of Roivant Sciences, continued to show promising results in an update from a study of healthy volunteers.
• Avidity Biosciences expanded its cardiovascular research partnership with Bristol Myers Squibb. Avidity will receive $100 million in upfront payments from Bristol for licensing rights to five cardiovascular drug targets.
• Novocure, maker of a medical device to treat brain cancer, announced a strategic restructuring to reduce overall costs, including layoffs affecting 13% of its workforce.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect